Biden
says Americans will be first to get vaccines; any surplus to be shared
Send a link to a friend
[March 11, 2021]
WASHINGTON (Reuters) - The U.S. government
will first give Americans COVID-19 vaccines, but any surplus would be
shared with the world, President Joe Biden said on Wednesday after
earlier announcing plans to procure an additional 100 million doses.
|
"We're going to start off and ensure Americans are taken care of
first, but we're then going to try to help the rest of the world,"
Biden told reporters following an earlier announcement to secure
more vaccines with the chief executives of Johnson & Johnson and
Merck.
"If we have a surplus, we're going to share it with the rest of the
world," Biden said, adding that the United States had already
committed to providing $4 billion to the COVAX global initiative to
distribute vaccines in developing countries.
The Democratic president said it was clear that the pandemic would
not be over until it was ended everywhere.
"We're not going to be ultimately safe, until the world is safe," he
said.
White House Press Secretary Jen Psaki told reporters that Biden was
deeply focused on expanding global vaccinations, but the U.S.
government was pushing to first ensure sufficient doses for people
in the United States who wanted to get vaccinated.
She said Biden was discussing the need to ensure vaccines got to
developing countries with his counterparts, but gave no details.
[to top of second column] |
The United States, Britain,
European Union nations and other richer members
of the World Trade Organization (WTO) on
Wednesday blocked a push by more than 80
developing countries to waive patent rights in
an effort to boost production of COVID-19
vaccines for poor nations.
South Africa and India are leading the push for
a temporary waiver of the rules of the WTO's
Trade-Related Aspects of Intellectual Property
(TRIPS) agreement, a move that could allow
generic or other manufacturers to make more
vaccines.
Western nations argue that protecting
intellectual property rights encourages research
and innovation, and suspending those rights
would not result in a sudden surge of vaccine
supply.
(Reporting by Andrea Shalal; Editing by Leslie
Adler and Aurora Ellis)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |